The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitorDuring the last two decades, the landscape for psoriasis treatment has exploded. The advent of biologic therapies at Share XThe key to psoriasis innovation? Dispelling the shadow of the JAK inhibitorhttps://pharmaphorum.com/partner-content/the-key-to-psoriasis-innovation-dispelling-the-shadow-of-the-jak-inhibitor/
Trials leave Galapagos’ SIK programme looking under the weatherGalapagos has had to send its SIK inhibitor programme back to the drawing board after its lead compound Share XTrials leave Galapagos’ SIK programme looking under the weatherhttps://pharmaphorum.com/news/trials-leave-galapagos-sik-programme-looking-under-the-weather/
Dermavant raises $200m to ease launch of Otezla rival tapinarofDermavant is in line to make some big payments to GlaxoSmithKline if its topical psoriasis drug tapinarof reaches Share XDermavant raises $200m to ease launch of Otezla rival tapinarofhttps://pharmaphorum.com/news/dermavant-raises-200m-to-ease-launch-of-otezla-rival-tapinarof/
Crowded psoriasis market cuts Lilly’s mirikizumab ambitionsEli Lilly has walked away from a major indication for its blockbuster hopeful mirikizumab, shelving plans to file Share XCrowded psoriasis market cuts Lilly’s mirikizumab ambitionshttps://pharmaphorum.com/news/crowded-psoriasis-market-cuts-lillys-mirikizumab-ambitions/
BMS’ deucravacitinib psoriasis pill could launch next year after outperforming Amgen’s rivalBristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in Share XBMS’ deucravacitinib psoriasis pill could launch next year after outperforming Amgen’s rivalhttps://pharmaphorum.com/news/bms-deucravacitinib-psoriasis-pill-could-launch-next-year-after-outperforming-amgens-rival/
Avillion/Merck psoriasis nanobody hits the mark in phase 2UK biotech Avillion has reported positive mid-stage results with chronic psoriasis drug sonelokimab, which it is developing with Share XAvillion/Merck psoriasis nanobody hits the mark in phase 2https://pharmaphorum.com/news/avillion-merck-psoriasis-nanobody-hits-the-mark-in-phase-2/
Sanofi licences in potential oral IL-17 drug from UK’s C4X DiscoverySanofi has licensed a potential inflammatory diseases drug from Manchester University spin-off C4X Discovery Holdings in a deal Share XSanofi licences in potential oral IL-17 drug from UK’s C4X Discoveryhttps://pharmaphorum.com/news/sanofi-licences-in-potential-oral-il-17-drug-from-uks-c4x-discovery/
Almirall, Happify partner on digital tool for psoriasis mental healthIt’s well recognised that people with psoriasis can develop depression or anxiety, particularly in moderate or severe cases Share XAlmirall, Happify partner on digital tool for psoriasis mental healthhttps://pharmaphorum.com/news/almirall-happify-partner-on-digital-tool-for-psoriasis-mental-health/
Global ‘PsoriasIS NOT CONTAGIOUS’ campaign for World Psoriasis Day 2020Fishawack Health launches global disease awareness campaign, supported by the community of Psoriasis Warriors to de-stigmatize psoriasis during Share XGlobal ‘PsoriasIS NOT CONTAGIOUS’ campaign for World Psoriasis Day 2020https://pharmaphorum.com/partner-content/global-psoriasis-not-contagious-campaign-for-world-psoriasis-day-2020/
